Skip to main content
Signal8

REVELATION BIOSCIENCES, INC. (REVB)

Revelation Biosciences, Inc. is a biopharmaceutical firm currently in its clinical development phase, dedicated to the advancement and commercialization of treatments and diagnostic tools targeting the immune system. The company's therapeutic pipeline includes promising candidates such as GEM-AKI, which is being developed as a potential therapy for both the prevention and management of acute kidney injury, and GEM-CKD, intended for the prevention and treatment of chronic kidney disease. Established in 2019, this San Diego, California-based enterprise was formerly known as Petra Acquisition, Inc., before officially adopting the name Revelation Biosciences, Inc. in January 2022.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Revelation Biosciences, Inc. logo

Revelation Biosciences, Inc.

NASDAQ:REVBHealthcare
AH-3.48%$3.74
Close$3.88+1.57%
Mkt Cap$2.65M
EV-
Float539K
O/S683K
VOL13K sh
$ Vol$50K
RVOL0.59×
Inst Own6.1%
SI2.4%
Net Cash/Sh-
Dilution
Revelation Biosciences, Inc. logoNASDAQ:REVBAH$3.74-3.48%

REVELATION BIOSCIENCES, INC. (REVB) dilution facts from SEC filings

Snapshot as of Sep 30, 2026, built from 33 SEC filings.

Shelf registration
S-3 filed Jan 30, 2026, effective Feb 11, 2026
Source: 10-Q filed Nov 5, 2026
At-the-market (ATM) program
No active program in the filings reviewed
Warrants outstanding
13 warrant series recorded as outstanding
Most recent offering
Offering, priced Jan 23, 2026
Source: 10-Q filed Nov 5, 2026

Check another stock for dilution

Facts as recorded in the company's SEC filings. The full snapshot, with instrument terms, share counts and history, is part of Signal8 Pro.

Unlock with Signal8 Pro